ADC Therapeutics completes LOTIS-7 enrollment in DLBCL study
- ADC Therapeutics completed enrollment in the Phase 1b LOTIS-7 trial of ZYNLONTA plus glofitamab.
- The study includes 100 patients with relapsed or refractory diffuse large B-cell lymphoma.
- Full clinical data readout is expected in the fourth quarter of 2026.
ADC Therapeutics (NYSE:ADCT) said it has completed enrollment in the LOTIS-7 Phase 1b clinical trial evaluating ZYNLONTA in combination with glofitamab for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
The study enrolled 100 patients across 30 clinical sites and is evaluating a 150 µg/kg dose of ZYNLONTA in combination with glofitamab.
ADC Therapeutics said the trial is designed to assess safety and early efficacy signals for the combination therapy in heavily pretreated lymphoma patients.
The company said full study data are expected in the fourth quarter of 2026.
ADC Therapeutics said ZYNLONTA remains a key asset in its oncology pipeline focused on CD19-targeted antibody-drug conjugate therapies.
The company also said combination approaches such as LOTIS-7 are aimed at improving outcomes in difficult-to-treat lymphoma settings.
More from United States
Arm Q2 revenue hits $1.44B as AI chip demand surges
Qualcomm Q4 earnings beat estimates as auto sales jump 89%
Melco Resorts Q3 revenue falls 10% to $1.17 billion
Emerson Q4 revenue accelerates 7% to $5.2 billion
Flowco Q3 revenue revs up 46% to $258.6 million
Clear secure Q3 revenue hits $292.9M as top line expands 27.8%
